A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

This Phase 3 placebo-controlled study is planned to further investigate the efficacy, safety, and tolerability of apraglutide in the overall SBS-IF (short bowel syndrome associated with intestinal failure) population during 24 weeks of study treatment. It is expected that approximately 124 participants will be randomized worldwide to either apraglutide or placebo in a 1:1 ratio in this trial.

NCT Number	NCT07742735
Lead Sponsor	VectivBio AG Collaborators: PSI CRO
Conditions	Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
Enrollment	124 participants
Start Date	2026-08
Primary Completion	2028-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-04